Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Safety Initiative Is Topic Of CDER/DIA Webcast May 20

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Acting Director Galson and Drug Safety Oversight Board Executive Director Cummins are among the panelists. Topics will include IoM's drug safety study, the Drug Watch website, and an update on the search for the Office of Drug Safety's new director.

You may also be interested in...

FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues

FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses

Drug Safety Oversight Board Will Require Two-Thirds Majority For Recommendations

FDA's Drug Safety Oversight Board will need a two-thirds majority of a quorum to make recommendations, a Center for Drug Evaluation & Research Manual of Policies & Procedures states

House Appropriations Subcommittee Plans FDA Hearing July 26

Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts